Câncer de Mama Online (Breast Cancer)
■ Management of cardiovascular disease in women with breast cancer
R Barish, F Lymce, K Unger, A Barac
Circulation 2019, vol 139: 1110-1120
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.039371
■ SEOM clinical guidelines in early stage breast cancer (2018)
- Ayala de la Peña, R. Andrés, J. A. Garcia-Sáenz, et al
Clin Transl Oncol. 2019; vol 21(1): 18–30
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339657/
■ 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F Cardoso, E Senkus, A Costa et al
Annals of Oncology 2018, vol 29 (8): 1634-1657
https://academic.oup.com/annonc/article/29/8/1634/5055519
■ Alterações na Modulação Autonômica Cardíaca em Mulheres com Câncer de Mama em Uso de Inibidores de Aromatase e sua Relação com Variáveis Bioquímicas
Gonzaga, Luana Almeida et al
Arq. Bras. Cardiol., May 2019, vol.112, no.5, p.555-563
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000500555&lng=pt&nrm=iso&tlng=pt (portuguese)
■ Alteração Contrátil Segmentar Ventricular Esquerda é Preditor Independente de Cardiotoxicidade em Pacientes com Câncer de Mama em Tratamento Quimioterápico
Barros, Márcio Vinícius Lins de et al
Arq. Bras. Cardiol., Jan 2019, vol.112, no.1, p.50-56
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2019000100050&lng=pt&nrm=iso&tlng=pt (portuguese)
■ Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board
S P Somashekhar, M –J Sepúlveda, S Publielli et al
Annals of Oncology 2018, vol 29 (2): 418-423
https://academic.oup.com/annonc/article/29/2/418/4781689
■ Genetic testing to guide risk-stratified screens for breast cancer
Ava Willoughby, Paul R. Andreassen, Amanda Ewart Toland
J Pers Med. 2019, vol 9(1): 15.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462925/
■ Overview of the genetic basis toward early detection of breast cancer
Sumadee De Silva, Kamani Hemamala Tennekoon, Eric Hamilton Karunanayake
Breast Cancer (Dove Med Press) 2019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345186/
■ Repercussions of melatonin on the risk of breast cancer: a systematic review and meta-analysis
Veiga, Eduardo Carvalho de Arruda et al.
Rev. Assoc. Med. Bras., May 2019, vol.65, no.5, p.699-705
■ Translation and cultural adaptation of the Breast Cancer Treatment Outcome Scale (BCTOS) into Brazilian Portuguese.
Vieira, René Aloisio da Costa et al.
Rev. Assoc. Med. Bras., July 2018, vol.64, no.7, p.627-634
■ . Influência do posicionamento do retalho linfonodal vascularizado na resposta ao tratamento cirúrgico do linfedema secundário ao câncer de mama..
Montag, Eduardo et al
Rev. Col. Bras. Cir., 2019, vol.46, no.2
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912019000200156&lng=en&nrm=is
■ Papel da ressonância magnética das mamas na avaliação do carcinoma ductal in situ.
Tajima, Carla Chizuru et al
Radiol Bras, Feb 2019, vol.52, no.1, p.43-47
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842019000100043&lng=en&nrm=iso&tlng=pt (portuguese)
■ The screening, diagnosis, treatment, and follow-up of breast cancer
A Wöckel, U Albert, W Janni et al
Dtsch Arztebl Int 2018, vol 115 (18): 316-323
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987060/
■ Risk-reducing mastectomy for the prevention of primary breast cancer
Liz Lostumbo, Judi Wallace, Henry Ko, Nora E Carbine
Cochrane Database Syst Rev. 2018 Apr; 2018(4): CD002748
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494635/
■ Epidemiological characteristics of an risk factors for breast cancer in the world
Zohre Momenimovahed, Hamid Salehiniya
Breast Cancer (Dove Med Press) 2019; 11: 151–164
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462164/
■ Axillary web syndrome following breast cancer surgery: symptoms, complications, and management strategies
LA Koehler, TC Haddad, DW Hunter, TM Tuttle
Breast Cancer (Dove Med Press) 2019; 11: 13–19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304256/
■ Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
Nehad M Ayoub, Kamal M Al-Shami, Rami J Yaghan
Breast Cancer (Dove Med Press) 2019; 11: 53–69. Published online 2019 Jan
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340364/
■ Targeting stem cells in the realm of drug-resistant breast cancer
Pranay Dey, Maitreyi Rathod, Abhijit De
Breast Cancer (Dove Med Press) 2019; 11: 115–135
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410754/
■ Metastasis inhibition in breast cancer by targeting cancer cell extravasation
Márcia R Cominetti, Wanessa F Altei, Heloisa Sobreiro Selistre-de-Araujo
Breast Cancer (Dove Med Press) 2019; vol 11: 165–178
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497883/
■ Stain use and breast cancer survival – a Swedish Nationwide study
Signe Borgquist, Per Broberg, Jasaman Tojjar, Håkan Olsson
BMC Cancer. 2019; 19: 54
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330431/
■ Sarcomas of the breast: findings on mammography, ultrasound, and magnetic resonance imaging
Matsumoto, Renato Augusto Eidy Kiota et al.
Radiol Bras, Dec 2018, vol.51, no.6, p.401-406
■ Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
T Bachelot, E Ciruelos, A Schneeweiss et al
Annals of Oncology 2018, vol 30 (5): 766-773
https://academic.oup.com/annonc/article/30/5/766/5364015
■ BEECH: a dose-finding run-in followed by a randomized phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancere, and in PIK3CA mutant sub-population
N C Turner, E Alarcón, A C Armstrong et al
Annals of Oncology 2018, vol 30 (5): 766-773
https://academic.oup.com/annonc/article/30/5/774/5376517
■ European cancer mortality predictions for the year 2019 with focus on breast cancer
M Malvezzi, G Carioli, P Bertuccio et al
Annals of Oncology 2018, vol 30 (5): 781-787
https://academic.oup.com/annonc/article/30/5/774/5376517
■ OlympiAD final overall survival and tolerability results: Olaparibib versus chemotherapy treatment of physician´s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M E Robson, N Tung, P Conte et al
Annals of Oncology 2018, vol 30 (4): 558-566
https://academic.oup.com/annonc/article/30/4/558/5299440
■ Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Acionability of molecular Targets (ESCAT)
R Condorelli, F Mosele, B Verret et al
Annals of Oncology 2018, vol 30 (3): 365-373
https://academic.oup.com/annonc/article/30/3/365/5305018
■ Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShorHER randomized adjuvant for patients with early HER2+ breast cancer
M V Dieci, P Conte, G Bisagni et al
Annals of Oncology 2018, vol 30 (3): 418-423
https://academic.oup.com/annonc/article/30/3/418/5290085
■ Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer
E S Sokol, Y X Feng, D X Jin et al
Annals of Oncology 2019, vol 30 (1): 115-123
https://academic.oup.com/annonc/article/30/1/115/5181087
■ Nine weeks versus 1 year adjuvant transtuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
P Conte, A Frassoldati, G Bisagni et al
Annals of Oncology 2018, vol 30 (12): 2328-2333
https://academic.oup.com/annonc/article/29/12/2328/5096775
■ Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of hign-risk luminal breast cancer
P Cottu, V D´Hondt, S Dureau et al
Annals of Oncology 2018, vol 29 (12): 2334-2340
https://academic.oup.com/annonc/article/29/12/2334/5126820
■ Mutational mechanism of amplifications revealed by analysis of clustered rearrangements in breast cancers
D Glodizik,, C Purdie, I H Rye et al
Annals of Oncology 2018, vol 29 (11): 2223-2231
https://academic.oup.com/annonc/article/29/11/2223/5106670
■ Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors
M Diossy,L Reiniger, Z Sztupinszki et al
Annals of Oncology 2018, vol 29 (9): 1948-1954
https://academic.oup.com/annonc/article/29/9/1948/5039891
■ nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D A Yardeley, R Coleman, P Conte et al
Annals of Oncology 2018, vol 29 (8): 1763-1770
https://academic.oup.com/annonc/article/29/8/1763/5033593
■ Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
F Poggio, M Bruzzone, M Ceppi et al
Annals of Oncology 2018, vol 29 (7): 1497-1508
https://academic.oup.com/annonc/article/29/7/1497/5026316
■ Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G N Hortobagyi, S M Stemmer, H A Burris et al
Annals of Oncology 2018, vol 29 (7): 1541-1547
https://academic.oup.com/annonc/article/29/7/1541/4989216
■ Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with and anthracycline and resistant to taxane
M Martin, M Campone, I Bondarenko et al
Annals of Oncology 2018, vol 29 (5): 1195-1202
https://academic.oup.com/annonc/article/29/5/1195/4852792
■ RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C Cruz, M Casgtroviejo-Bermejo, S Gutiérrez-Enríquezet al
Annals of Oncology 2018, vol 29 (5): 1203-1210
https://academic.oup.com/annonc/article/29/5/1203/4959904
■ Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer
R J hartmaier, S E Trabucco, N Priedigkeit et al
Annals of Oncology 2018, vol 29 (4): 872-880
https://academic.oup.com/annonc/article/29/4/872/4817340
■ Open-label randomized phase III trial of vinflunine versus and alkylating agent in patients with heavily pretreated metastatic breast cancer
J Cortes, J Perez-Garcia, C Levy et al
Annals of Oncology 2018, vol 29 (4): 881-887
https://academic.oup.com/annonc/article/29/4/881/4897992
■ Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
H S Rugo, V Diéras, K A Gelmon et al
Annals of Oncology 2018, vol 29 (4): 888-894
https://academic.oup.com/annonc/article/29/4/888/4817337
■ Unravelling triple-negative breast cancer molecular hereogeneity using an integrative multiomic analysis
Y Bareche, D Venet, M Ignatiadis et al
Annals of Oncology 2018, vol 29 (4): 895-902
https://academic.oup.com/annonc/article/29/4/895/4819112
■ Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers
N J Birkbak, Y Li, S Pathania et al
Annals of Oncology 2018, vol 29 (4): 903-909
https://academic.oup.com/annonc/article/29/4/903/4857262
■ Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R Condorelli, L Spring, J O´Shaughnessy, L Lacroix et al
Annals of Oncology 2018, vol 29 (3): 640-645
https://academic.oup.com/annonc/article/29/3/640/4725051
■ Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
S M Swain, M S Ewer, G Viale et al
Annals of Oncology 2018, vol 29 (3): 646-653
https://academic.oup.com/annonc/article/29/3/646/4748818
■ Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)
P Sharma, W E Barlow, A K Godwin et al
Annals of Oncology 2018, vol 29 (3): 654-660
https://academic.oup.com/annonc/article/29/3/654/4774220
■ A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
A Gennary, Z Sun, U Hasler-Strub et al
Annals of Oncology 2018, vol 29 (3): 661-668
https://academic.oup.com/annonc/article/29/3/661/4710349
■ Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with an withut visceral metastases
N C Turner, R S Finn, M Martin et al
Annals of Oncology 2018, vol 29 (3): 669-680
https://academic.oup.com/annonc/article/29/3/669/4802189
■ Tracking evolution of aromatase inhibitor resistance with circulating tumor DNA analysis in metastatic breast cancer
C Fribbens, I G Murillas, M Beaney et al
Annals of Oncology 2018, vol 29 (1): 145-153
https://academic.oup.com/annonc/article/29/1/145/4344806
■ Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
H S Han, V Diéras, M Robson et al
Annals of Oncology 2018, vol 29 (1): 154-161
https://academic.oup.com/annonc/article/29/1/154/4282670
■ A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer
C Criscitiello, M A Bayar, G Curigliano et al
Annals of Oncology 2018, vol 29 (1): 162-169
https://academic.oup.com/annonc/article/29/1/162/4565501
■ A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
P Nuciforo, T Pascual, J Cortés et al
Annals of Oncology 2018, vol 29 (1): 170-177
https://academic.oup.com/annonc/article/29/1/170/4460101
■ Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
V Möbus, C Jackisch, H J Lück et al
Annals of Oncology 2018, vol 29 (1): 178-185
https://academic.oup.com/annonc/article/29/1/178/4563565
■ Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients
N Nabieva, S Kellner, T Fehm et al
Annals of Oncology 2018, vol 29 (1): 186-192
https://academic.oup.com/annonc/article/29/1/186/4430373
■ Dr Paulo Fernando Leite
Cardiologia/Prevenção Cardiovascular
Estratificação de Risco Cardiovascular
Novo endereço:
Consultório: Rua Padre Rolim 815/sala 815
Tel: 33245518 (Consulta Particular/Unimed)
– Centro Médico Unimed BH/Contagem/Pedro I
Belo Horizonte/MG/Brasil
CRMMG: 7026
Email: pfleite1873@gmail.com